Clinical Trial News and Research

RSS

IRX Therapeutics signs research collaboration agreement with world's leading pharma companies

IRX Therapeutics, a developer of immune therapies to make cancer treatments better, announced today it has signed a research collaboration agreement with one of the world's leading research-based pharmaceutical companies.

1 Mar 2011

Millennium, Seattle commence brentuximab vedotin phase I trial in patients with ALCL

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company today announced that they have initiated a phase I clinical trial of brentuximab vedotin in combination with chemotherapy for the treatment of newly diagnosed systemic anaplastic large cell lymphoma patients.

1 Mar 2011

High blood pressure medications useful even in those without hypertension: Study

Researchers have studied existing evidence to suggest that people who have had a stroke or a heart attack might benefit from taking blood pressure medications, even if they do not have high blood. They noted that for every 1,000 people taking the drugs in clinical trials, on average 15 fewer died from heart disease than when the patients got dummy treatment. The study however could not explain the cause for this benefit. The study, which was funded by Tulane University and the National Institutes of Health, was published in the March 2 issue of the Journal of the American Medical Association.

1 Mar 2011

QLT fourth quarter revenues decrease 7.3% to $10.0 million

QLT Inc. today reported financial results for the fourth quarter ended December 31, 2010 and full year 2010 as well as issued its guidance for 2011. Unless specified otherwise, all amounts are in U.S. dollars and in accordance with U.S. GAAP.

1 Mar 2011

International conference to address pediatric congenital cataract treatment in New York City

An international conference addressing the treatment of children born with a cataract will take place in New York City on Friday, March 11, 2011.

1 Mar 2011

FDA approves Forest Labs' Daliresp to treat COPD

Forest Laboratories, Inc. announced today that Daliresp was approved by the U.S. Food and Drug Administration as a treatment to reduce the risk of chronic obstructive pulmonary disease exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations.

1 Mar 2011

Intercell reports EUR 255.2m net loss for full year 2010

Today Intercell AG announced its financial results for Q4 and the preliminary results for the full financial year 2010 and presented an update on the Company's development programs.

1 Mar 2011

Chromosomally unstable bowel cancer cells more resistant to chemotherapy treatments, targeted drugs

Cancer Research UK scientists have made an important step towards developing personalised bowel cancer treatment by identifying which tumours are more likely to become drug resistant, according to research published in Cancer Research today.

1 Mar 2011

New personalized therapy fools cancer cells into killing themselves

A Wayne State University School of Medicine physician-researcher has developed a personalized therapy to treat a wide range of cancers. The treatment is based on a naturally occurring human enzyme that has been genetically modified to fool cancer cells into killing themselves.

1 Mar 2011

Sweden's TLV confirms reimbursement for Qutenza patch for treatment of peripheral neuropathic pain

Patients in Sweden living with peripheral neuropathic pain are set to gain access to a new treatment option which can provide pain relief for up to three months following a single 30- or 60-minute application. The new treatment patch uses capsaicin - the substance found in chilli peppers which gives them their 'heat' - to change the function of pain sensing nerves in the area of skin affected.

1 Mar 2011

Derycz Scientific to acquire TAAG for 368,000 shares of common stock

Derycz Scientific, Inc., a company pioneering a fresh way of facilitating information flow from content publishers to enterprise customers and their constituents, today announced it has signed an agreement to acquire Techniques Appliquees aux Arts Graphiques, S.p.A. for 368,000 shares of Derycz common stock in addition to an earn-out.

1 Mar 2011

Nile plans to develop novel therapeutics for ADHF

Nile Therapeutics, Inc., a biopharmaceutical company focused on the development of novel therapeutics for cardiovascular disease, announced plans to pursue a new indication in the field of heart failure.

1 Mar 2011

CellSeed, LA BioMed enter two-year research agreement to study core technology in regenerative medicine

Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center and CellSeed Inc., a Japanese biotechnology firm, have entered into a two-year research agreement to study CellSeed's proprietary core technology in regenerative medicine, "Cell Sheet Engineering," LA BioMed President and CEO David I. Meyer, PhD, announced today.

28 Feb 2011

Omni Bio to expand Type 1 diabetes Phase I/II trial from 15 to 50 patients

Omni Bio Pharmaceutical, Inc., an emerging biopharmaceutical company formed to acquire, license, and develop existing therapies for indications with substantial commercialization potential, has committed to expand its Phase I/II human clinical trial in recently diagnosed Type 1 diabetes patients from 15 patients to 50.

28 Feb 2011

EPO grants three core patents to caprotec's CCMS technology

caprotec bioanalytics GmbH announced today that the European Patent Office has granted the last of three core patents protecting its proprietary and revolutionary Capture Compound Mass Spectrometry technology.

28 Feb 2011

ACT Biotech files SPA with FDA for telatinib combination Phase 3 trial for stomach cancer

ACT Biotech, Inc., a biopharmaceutical company focused on the development of highly targeted, oral therapeutics for the treatment of cancer, announced today that it has filed a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA) related to a randomized Phase 3 trial of telatinib in combination with chemotherapy for the first-line treatment of patients with advanced stomach cancer.

28 Feb 2011

BrainStorm raises $3.6 million through private placement financing

BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies and therapeutics, announced today that it has entered into securities purchase agreements with certain institutional and other investors in connection with a private placement financing in reliance upon Regulation S. BrainStorm received gross proceeds of approximately $3.6 million resulting from the sale of shares at a purchase price of $0.28 per share at the closing of the transaction.

28 Feb 2011

Tenofovir gel may help reduce risk of HIV from anal sex

A gel developed to protect against HIV during vaginal sex produced a strong antiviral effect when used in the rectum, according to an early-phase study presented today at the 18th Conference on Retroviruses and Opportunistic Infections (CROI). The results, based on rectal tissue biopsies sampled from HIV-negative men and women who used the product daily for one week, provide the first-ever evidence that tenofovir gel could help reduce the risk of HIV from anal sex, even though the vaginal gel formulation may not be optimal for rectal use.

28 Feb 2011

Positive results from Trius torezolid Phase 1 lung study

Trius Therapeutics, Inc. today announced results from its Phase 1 clinical trial to evaluate the ability of torezolid to penetrate into the lung for potential use to treat lung infections. In this study a 200 mg dose of torezolid phosphate was administered orally once-daily for three days to healthy adult volunteers. The trial achieved its primary goal of establishing the steady-state plasma pharmacokinetics and distribution of active drug into epithelial lining fluid (ELF).

28 Feb 2011

Immunitor to present latest results from imm01 trial in tuberculosis patients at African conference

Immune Network Ltd. advises that Immunitor will present latest results from its imm01 clinical trial in tuberculosis patients in Abuja, Nigeria at the 18th Union TB and Lung Diseases Conference of the African Region, 2nd to 5th March, 2011.

28 Feb 2011

Clinical Trial News and Research

IRX Therapeutics signs research collaboration agreement with world's leading pharma companies

Millennium, Seattle commence brentuximab vedotin phase I trial in patients with ALCL

High blood pressure medications useful even in those without hypertension: Study

QLT fourth quarter revenues decrease 7.3% to $10.0 million

International conference to address pediatric congenital cataract treatment in New York City

FDA approves Forest Labs' Daliresp to treat COPD

Intercell reports EUR 255.2m net loss for full year 2010

Chromosomally unstable bowel cancer cells more resistant to chemotherapy treatments, targeted drugs

New personalized therapy fools cancer cells into killing themselves

Sweden's TLV confirms reimbursement for Qutenza patch for treatment of peripheral neuropathic pain

Derycz Scientific to acquire TAAG for 368,000 shares of common stock

Nile plans to develop novel therapeutics for ADHF

CellSeed, LA BioMed enter two-year research agreement to study core technology in regenerative medicine

Omni Bio to expand Type 1 diabetes Phase I/II trial from 15 to 50 patients

EPO grants three core patents to caprotec's CCMS technology

ACT Biotech files SPA with FDA for telatinib combination Phase 3 trial for stomach cancer

BrainStorm raises $3.6 million through private placement financing

Tenofovir gel may help reduce risk of HIV from anal sex

Positive results from Trius torezolid Phase 1 lung study

Immunitor to present latest results from imm01 trial in tuberculosis patients at African conference

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (2nd Edition)

BFEB: Advances in microplate-based assays and analysis

Biologics stability screening toolkit: Three practical workflows for accelerating formulation development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery